- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00002046
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
Study Overview
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- Univ of Arizona / Health Science Ctr
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Univ Med School
-
Chicago, Illinois, United States, 60612
- Rush Presbyterian - Saint Luke's Med Ctr
-
Chicago, Illinois, United States, 60612
- Cook County Hosp
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Hosp
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Univ of Missouri at Kansas City School of Medicine
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- Univ of New Mexico Hlth Sciences Ctr / Dept of Med
-
-
New York
-
Manhasset, New York, United States, 11030
- Northshore Hosp / Cornell Univ
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Univ of Pennsylvania / HIV Clinic
-
-
Texas
-
Galveston, Texas, United States, 77550
- Univ TX Galveston Med Branch
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Treatment:
Allowed:
- Electron beam therapy to an area of less than 100 cm2.
Patients with the following are excluded:
- Any immediately life-threatening infection or medical condition present at the time of study entry.
- Any active opportunistic or other infection requiring chronic therapy present at the time of study entry.
Patients with Pneumocystis carinii pneumonia (PCP) may be randomized to study medication following a minimum 7-day course of therapy resulting in stabilization of their disease. Patients with stabilized disease must have fever < 39 degrees C for at least 48 hours; oxygen (on room air)
= or > 60 mm, and arterial / alveolar gradient = or < 30 mm.
- Kaposi's sarcoma, lymphoma, or other tumor likely to require cytotoxic chemotherapy.
Seropositive for HIV antibody documented by any federally licensed ELISA.
Patients must have ability to give informed consent and advanced HIV disease defined as:
- History of Pneumocystis carinii pneumonia (PCP) with histologic verification within 4 months of study entry.
OR History of other opportunistic infection included in the CDC surveillance definition of AIDS (stage IV-C-1), diagnosed within 4 months of entry, but not requiring chronic suppressive therapy, and a CD4+ cell count < 200 cells/mm3.
OR AIDS related complex (ARC) only those patients with a CD4+ count < 200 cells/mm3 and documentation of at least two signs or symptoms from the list below. One sign or symptom must be weight loss or candidiasis as described.
- Unexplained weight loss > 10 percent or = or > 15 lbs within the previous 4 months; with low weight at entry.
- History of mucocutaneous oral candidiasis (by culture or potassium hydroxide KOH smear).
- Fever > 38 degrees C, without documented infectious cause present, persisting > 1 month.
- Oral hairy leukoplakia.
- Unexplained night sweats, persisting > 1 month.
- Herpes zoster infection within 3 months of entry.
- Chronic diarrhea of unknown infectious etiology persisting > 1 month after 3 samples have been done eliminating ova, parasites, Cryptosporidia, Mycobacterium avium intracellulare, cytomegalovirus (CMV), and other pathogens associated with diarrheal disease in AIDS patients.
Negative Venereal Disease Research Laboratory (VDRL) or Rapid Plasma Reagent (RPR) or, if positive and verified by Fluorescent Treponemal Antibody Absorption (FTAABS), documented history of treatment for syphilis. If FTAABS is positive, but treatment history is not available, the patient may be entered 3 or more days following the initiation of appropriate chemotherapy.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- Chronic herpes virus infection.
- Fever > 39 degrees C at study entry.
- Known hypersensitivity to lactate and/or gelatin.
- Kaposi's sarcoma, lymphoma, or other tumor likely to require cytotoxic chemotherapy.
- Impaired renal function.
- AIDS dementia complex.
Concurrent Medication:
Excluded:
- Drugs which cause significant bone marrow suppression.
- Rifampin or rifampin derivatives.
- Drugs which cause significant nephrotoxicity or hepatotoxicity.
- Antiretroviral agents, including ribavirin, dideoxycytidine, dideoxyadenosine, didanosine, foscarnet, dextran sulfate, and AL-721.
- Acyclovir therapy of more than 21 days duration.
Concurrent Treatment:
Excluded:
- Radiation therapy (with the exception of electron beam therapy to an area of less than 100 cm2).
- Experimental therapy.
- Cytolytic chemotherapy.
Prior Medication:
Excluded:
- Acyclovir therapy of more than 21 days duration.
- Zidovudine (AZT).
- Excluded within 2 weeks of study entry:
- Drugs which cause significant bone marrow suppression.
- Rifampin or rifampin derivatives.
- Drugs which cause significant nephrotoxicity or hepatotoxicity.
- Immunomodulating agents, including pharmacologic doses of steroids for > 10 days.
- Excluded within 4 weeks of study entry:
- Interferon.
- Isoprinosine.
- IL-2.
- Excluded within 8 weeks of study entry:
- Antiretroviral agents, including ribavirin, dideoxycytidine, dideoxyadenosine, didanosine, foscarnet, dextran sulfate, and AL-721.
Prior Treatment:
Excluded:
- Radiation therapy (with the exception of electron beam therapy to an area of less than 100 cm2).
- Experimental therapy.
- Cytolytic chemotherapy.
Active drug or alcohol abuse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Zidovudine
Other Study ID Numbers
- 014G
- 18
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Zidovudine
-
Glaxo WellcomeUnknownHIV InfectionsUnited States
-
Institut de Recherche pour le DeveloppementEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV Infections | PregnancyThailand
-
Glaxo WellcomeCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Glaxo WellcomeCompleted
-
Glaxo WellcomeCompletedHIV Infections | LipodystrophyUnited States
-
Universidad Peruana Cayetano HerediaMerck Sharp & Dohme LLCCompletedHTLV-I Infections | Tropical Spastic ParaparesisPeru
-
University of Colorado, DenverNational Institute of Allergy and Infectious Diseases (NIAID); University of...Completed
-
ViiV HealthcareCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV InfectionsUnited States, Puerto Rico